- SGMO DD Number 3: Event Timeline, Short Interest and Evidence https://investors.biogen.com/news-releases/news-release-details/biogen-and-sangamo-announce-global-collaboration-develop-gene 110 comments wallstreetbets
- Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease | Biogen http://investors.biogen.com/news-releases/news-release-details/biogen-and-eisai-discontinue-phase-3-engage-and-emerge-trials 4 comments science